-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
According to the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, the Class 1 new drug BMS-986278-01, declared by Bristol-Myers Squibb Company (BMS), has been approved for two clinical trials in China, with special indications.
Image source: CDE official website screenshot
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal fibrotic lung disease
Studies have found that the biologically active lysobisphosphatidic acids (LPA) and LPA1 receptors are related to the etiology and pathogenesis of IPF.
BMS-986278 is a new next-generation LPA1 antagonist being developed by Bristol-Myers Squibb, which is intended for the treatment of pulmonary fibrosis (Pulmonary Fibrosis)
Image source: Screenshot of Bristol-Myers Squibb's official website
According to a study published in 2019, in cells expressing human LPA1 heterologously and primary human lung fibroblasts, BMS-986278 is a potent and complete antagonist of the effects of LPA on multiple signaling pathways mediated by LPA1
A query on the Clinicaltrials.
With the approval of the BMS-986278-01 tablet in China, clinical research is expected to be promoted in China
references:
[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.
